Corbus Pharmaceuticals Holdings, Inc. (CRBP): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biopharmaceutical company navigates the complex world of drug development and commercialization? Corbus Pharmaceuticals Holdings, Inc. (CRBP), currently trading at around $0.20 per share, focuses on innovative medicines targeting inflammatory, fibrotic, and metabolic diseases. This article dives into Corbus Pharmaceuticals, exploring its history, ownership structure, core mission, operational mechanisms, and revenue generation strategies, inviting you to understand its pivotal role in addressing unmet medical needs.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) History

Founding Timeline

Year established

The company was founded in 2009.

Original location

The company is headquartered in Westwood, Massachusetts.

Founding team members

Details on the specific founding team members are not readily available in the provided search results.

Initial capital/funding

Specific details regarding the initial capital or funding for the company's establishment are not available in the provided search results.

Evolution Milestones

Transformative Moments

• Reverse Merger (2014): The reverse merger marked a pivotal moment, transforming the company into a publicly traded entity and opening avenues for raising capital to support its drug development programs.
• Lenabasum Development and Setbacks: Development and subsequent setbacks with Lenabasum, particularly the discontinuation of its clinical program for systemic sclerosis in 2020, led to a strategic re-evaluation and shift in focus.
• Strategic Shift to Oncology: The pivot towards oncology with CRB-701 represented a significant transformation, leveraging a new technology platform (ADC) and targeting a different therapeutic area with substantial market potential.
• Focus on CRB-913 (2024): Announced FDA clearance of IND application for CRB-913, a selective agonist of the cannabinoid receptor type 1 (CB1), designed to target the underlying cause of anxiety and obesity.

For more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Corbus Pharmaceuticals Holdings, Inc. (CRBP).

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Ownership Structure

Understanding the ownership structure of Corbus Pharmaceuticals Holdings, Inc. provides insights into who controls the company and whose interests are most closely tied to its performance.

Corbus Pharmaceuticals Holdings, Inc. Current Status

Corbus Pharmaceuticals Holdings, Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange.

Corbus Pharmaceuticals Holdings, Inc. Ownership Breakdown

The ownership of Corbus Pharmaceuticals is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. As of the fiscal year 2024, the ownership breakdown is as follows:

Corbus Pharmaceuticals Holdings, Inc. Leadership

The leadership team is responsible for the strategic direction and operational management of Corbus Pharmaceuticals Holdings, Inc. Key members of the leadership team as of April 2025 include:

• Yuval Cohen, Ph.D.: Chief Executive Officer
• Robert Discordia: Chief Financial Officer
• Dr. Timothy Fazio: Chief Medical Officer

These individuals, along with other members of the executive team, guide the company's strategy, oversee its operations, and work to create value for shareholders. You might also be interested in: Mission Statement, Vision, & Core Values of Corbus Pharmaceuticals Holdings, Inc. (CRBP).

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Mission and Values

Corbus Pharmaceuticals is dedicated to pioneering innovative medicines that significantly improve the lives of people affected by rare, chronic, and serious diseases. The company's core values emphasize scientific rigor, patient-centricity, and a commitment to making a meaningful impact on healthcare.

Corbus Pharmaceuticals' Core Purpose

Official mission statement

While Corbus Pharmaceuticals doesn't have a single, publicly emphasized official mission statement, their core purpose can be understood through their actions and focus:

• Developing and commercializing innovative therapies to treat rare, chronic, and serious diseases with clear unmet needs.
• Focusing on indications where the endocannabinoid system (ECS) can play a crucial role.
• Advancing scientific understanding of the ECS and its therapeutic potential.

Vision statement

Corbus Pharmaceuticals envisions becoming a leader in the development of novel therapeutics targeting the endocannabinoid system to address significant unmet needs in rare and serious diseases.

• To be recognized as a premier biopharmaceutical company dedicated to transforming the lives of patients with rare and chronic diseases.
• To lead the way in ECS-targeted therapies, providing innovative solutions where few or no options currently exist.
• To build a sustainable and growing company that delivers value to its stakeholders, including patients, employees, and shareholders.

Company slogan/tagline

Corbus Pharmaceuticals does not currently have a widely publicized official slogan or tagline. However, the essence of their work could be captured by:

• 'Targeting the ECS, Transforming Lives.'
• 'Innovation for Rare Diseases.'
• 'Unlocking the Potential of the Endocannabinoid System.'

To gain more insights into Corbus Pharmaceuticals, explore: Exploring Corbus Pharmaceuticals Holdings, Inc. (CRBP) Investor Profile: Who’s Buying and Why?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) How It Works

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory, fibrotic, and metabolic diseases with clear unmet needs.

Corbus Pharmaceuticals' Product/Service Portfolio

As of April 2025, Corbus Pharmaceuticals is primarily focused on the development of its pipeline and does not have products commercially available. Therefore, the table below reflects the investigational products and their target markets.

Corbus Pharmaceuticals' Operational Framework

Corbus Pharmaceuticals operates through a focused drug development process. Key aspects of their operations include:

• Research and Development: Investing in preclinical and clinical studies to evaluate the safety and efficacy of their drug candidates.
• Clinical Trials: Conducting Phase 1, Phase 2, and Phase 3 clinical trials to gather data and seek regulatory approval.
• Regulatory Affairs: Working closely with regulatory agencies such as the FDA in the United States to navigate the drug approval process.
• Partnerships: Collaborating with other pharmaceutical companies, research institutions, and patient advocacy groups to advance their programs.
• Intellectual Property: Securing and maintaining patents to protect their drug candidates and technologies.

Corbus Pharmaceuticals' Strategic Advantages

Corbus Pharmaceuticals aims to establish a competitive edge through:

• Novel Therapeutic Candidates: Focusing on developing first-in-class or best-in-class therapeutics that address unmet medical needs.
• Targeted Approach: Developing drugs that selectively target specific pathways involved in disease, potentially leading to improved efficacy and safety profiles.
• Experienced Management Team: Leveraging the expertise of their leadership team in drug development, regulatory affairs, and commercialization.
• Strong Intellectual Property Portfolio: Building a robust patent portfolio to protect their drug candidates and maintain market exclusivity.

To gain more insights into the investors and ownership structure, you might find this resource helpful: Exploring Corbus Pharmaceuticals Holdings, Inc. (CRBP) Investor Profile: Who’s Buying and Why?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) How It Makes Money

Corbus Pharmaceuticals Holdings, Inc. operates as a clinical-stage pharmaceutical company, currently without products approved for sale, and thus generates revenue primarily through collaborative agreements, grants, and other research and development activities.

Corbus Pharmaceuticals Holdings, Inc. Revenue Breakdown

As a clinical-stage pharmaceutical company, Corbus Pharmaceuticals does not currently generate revenue from product sales. Instead, its revenue streams are tied to research and development activities, collaborations, and grants.

Corbus Pharmaceuticals Holdings, Inc. Business Economics

Corbus Pharmaceuticals' business economics are centered around the high-risk, high-reward model typical of clinical-stage pharmaceutical companies. Key aspects include:

• R&D Investment: A significant portion of operating expenses is dedicated to research and development, particularly clinical trials for its drug candidates.
• Intellectual Property: The company relies heavily on patents and proprietary technology to protect its drug candidates and maintain a competitive advantage.
• Partnerships: Strategic alliances and collaborations with other pharmaceutical companies or research institutions can provide funding, expertise, and resources.
• Funding: Corbus Pharmaceuticals primarily relies on equity financing, debt financing, and grants to fund its operations. Successful clinical trial outcomes and regulatory approvals are critical for attracting investment.

Corbus Pharmaceuticals Holdings, Inc. Financial Performance

Given its status as a clinical-stage company, traditional financial metrics may not fully reflect Corbus Pharmaceuticals' potential. However, key indicators of its financial health include:

• Cash Runway: Monitoring the company's cash reserves and burn rate is crucial to assess its ability to fund ongoing clinical trials and operations.
• R&D Expenses: Analyzing trends in R&D spending provides insights into the company's investment in its drug pipeline.
• Net Loss: As is typical for clinical-stage companies, Corbus Pharmaceuticals experiences net losses due to the absence of product revenue and substantial R&D costs.
• Stock Performance: The company's stock price is highly sensitive to clinical trial results, regulatory developments, and financing announcements.

To gain more insights into the company's investors and their motivations, check out this article: Exploring Corbus Pharmaceuticals Holdings, Inc. (CRBP) Investor Profile: Who’s Buying and Why?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Market Position & Future Outlook

Corbus Pharmaceuticals is strategically positioned as an oncology and obesity company with a diversified portfolio, holding a promising outlook with its clinical pipeline advancements and a cash runway extending through Q3 2027.

Competitive Landscape

Opportunities & Challenges

Industry Position

Corbus Pharmaceuticals is making significant strides in the competitive biopharmaceutical industry, particularly with its oncology and obesity pipelines:

• Cash Position: As of December 31, 2024, the company had approximately $149.1 million in cash, cash equivalents, and investments, expected to fund operations through Q3 2027.
• CRB-701: This next-generation antibody-drug conjugate (ADC) targeting Nectin-4 has shown promising safety and efficacy data in Phase 1 studies, with clinical responses observed in urothelial and cervical cancer.
• CRB-601: The first patient was dosed in December 2024 in a Phase 1 study for this anti-integrin monoclonal antibody, with dose escalation expected to complete in Q4 2025.
• CRB-913: IND-enabling studies are complete, and the first patient dosing in a Phase 1 study is expected in March 2025 for this CB1 receptor inverse agonist designed to treat obesity.

The company's strategic focus on precision oncology and obesity, coupled with a strong cash position, positions it favorably for future growth, despite inherent risks in the biopharmaceutical industry.

Learn more about the investors behind Corbus Pharmaceuticals: Exploring Corbus Pharmaceuticals Holdings, Inc. (CRBP) Investor Profile: Who’s Buying and Why?